Table 2.

Summary of the current literature on FUBP1 deregulation in solid cancers

Cancer	Deregulation	Downstream targets	Phenotypic effect	References
Oligodendrogliomas	Inactivating mutations of FUBP1	NA		[9, 13, 103–106, 110, 159–162]
Gliomas (other subtypes)	FUBP1 ↑	MYC ↑	G1/S cell cycle transition ↑	[15]
Hepatocellular carcinoma	FUBP1 ↑	MYC ↑	Proliferation ↓	[126]
		Stathmin 1/3 ↑	Migration ↑	[6]
		P21 ↓, P15 ↓, TNF-α ↓, TRAIL ↓, BIK ↓, NOXA ↓, CCND2 ↑	Proliferation ↑, apoptosis ↓	[8]
		PE2 upregulates FUBP1	Proliferation ↑, apoptosis ↓	[163]
		P53 ↓, P21 ↓, BCCIP ↓, TCTP ↑	Cell sensitivity to irradiation ↓	[70]
		FIR upregulates FUBP1		[7]
		P21 ↓, BIK ↓, CCND2 ↑, TCTP ↑		[11]
		PI3K/AKT/mTOR upregulate FUBP1		[164]
Gastric cancer	FUBP1 ↑	NA		[35, 165]
	FUBP1 ↑	MYC ↑	Tumor growth ↑	[34]
Colorectal carcinoma	FIR ↑ and FIR splice variant: FIR del/exon2	Absence of MYC repression	Resistance to apoptosis ↑, tumor growth ↑	[56, 134]
	FUBP1 ↑	NA		[166]
Breast cancer	FUBP1 ↑	MYC ↑	Proliferation ↑, tumor growth ↑	[34]
Clear cell renal cancer	FUBP1 ↑	MYC ↑		[24]
		MYC ↑, P21 ↑	Proliferation ↑, apoptosis ↓	[10]
Bladder cancer	FUBP1 ↑	NA (not MYC)		[24]
Ovarian cancer cells	FUBP1 ↑	NA		[167]
		NA	Resistance ↑	[117, 118]
Prostate cancer	FUBP1 ↑	NA (not MYC)		[24]
Nasopharyngeal carcinoma	FUBP1 ↑	MYC ↑	Proliferation ↑, colony formation ↑ and resistance ↑	[116]
		MYC	Resistance ↑	[168]
Esophageal squamous cell carcinoma	FUBP1 ↑	MYC ↑	Proliferation ↑, G1/S cell cycle transition ↑	[14]
Non-small cell lung cancer	FUBP1 ↑	Stathmin 1/3 ↑	Proliferation ↑, migration ↑ and matrix invasion ↑	[12]
		FIR ↑ FUBP1		[130]
Sacral chordomas	FUBP1 ↑	MYC ↑	Proliferation ↑, invasion ↑	[127]

NA not available